ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
22.539,98
1,71%
S&P 500
5.633,07
0,38%
Dow Jones
41.989,96
-0,03%
Euro vs US Dollar
1,07921
-0,03%
Bitcoin
84.319,70
-1,00%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. AMEX
  6. Can Fite BioPharma Ltd (CANF)

  7. Can Fite BioPharma Ltd (CANF) News

CANF

Can Fite BioPharma (CANF)

Can Fite BioPharma Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:AMEX:CANF
DatumZeitQuelleÜberschriftSymbolFirma
24/03/202514h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
24/03/202514h00GlobeNewswire Inc.Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved ProtocolAMEX:CANFCan Fite BioPharma Ltd
20/03/202514h45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
20/03/202514h45GlobeNewswire Inc.Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion MarketAMEX:CANFCan Fite BioPharma Ltd
19/03/202514h02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
19/03/202514h00GlobeNewswire Inc.Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with PiclidenosonAMEX:CANFCan Fite BioPharma Ltd
18/03/202513h32Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
18/03/202513h30GlobeNewswire Inc.Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer PatientAMEX:CANFCan Fite BioPharma Ltd
03/03/202512h04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
03/03/202512h00GlobeNewswire Inc.Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological BenefitsAMEX:CANFCan Fite BioPharma Ltd
18/02/202513h04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
18/02/202513h00GlobeNewswire Inc.Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's NamodenosonAMEX:CANFCan Fite BioPharma Ltd
14/02/202523h33Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]AMEX:CANFCan Fite BioPharma Ltd
10/02/202513h10GlobeNewswire Inc.Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25AMEX:CANFCan Fite BioPharma Ltd
05/02/202513h02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
05/02/202513h00GlobeNewswire Inc.Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025AMEX:CANFCan Fite BioPharma Ltd
27/01/202513h03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
27/01/202513h00GlobeNewswire Inc.US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity DrugAMEX:CANFCan Fite BioPharma Ltd
30/12/202413h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
30/12/202413h00GlobeNewswire Inc.Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug NamodenosonAMEX:CANFCan Fite BioPharma Ltd
04/12/202413h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
04/12/202413h00GlobeNewswire Inc.8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson DrugAMEX:CANFCan Fite BioPharma Ltd
14/11/202422h48Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]AMEX:CANFCan Fite BioPharma Ltd
11/11/202413h00GlobeNewswire Inc.Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical TrialAMEX:CANFCan Fite BioPharma Ltd
04/11/202413h09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
04/11/202413h08GlobeNewswire Inc.Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in AustraliaAMEX:CANFCan Fite BioPharma Ltd
18/10/202415h23Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
18/10/202415h06GlobeNewswire Inc.Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with PiclidenosonAMEX:CANFCan Fite BioPharma Ltd
09/10/202413h03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
09/10/202413h00GlobeNewswire Inc.FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic CancerAMEX:CANFCan Fite BioPharma Ltd
 Showing the most relevant articles for your search:AMEX:CANF

Kürzlich von Ihnen besucht

COIN
YBANUSD
BananoDOS
BOV
CABI3
Cabinda Participacoes ON
LSE
HMWS
Hsbc Msci Wd Ac
BITMOT
808942
Eib Tf 8% Ge27 Mxn
BIT
XBLC
iBoxx EUR LIQUID CORPORA...
BIBX
NEOETH
NEO
EU
MIVU
Amundi Msci Usa Minimum ...
TSXV
NBM
NEO Battery Materials
BIT
XSPX
S&P 500 ETF Class 1C sha...
BOV
SOMA3
Grupo De Moda Soma ON
BIT
WCCA
Wisdomtree California Ca...
TSX
CVE.PR.B
Cenovus Energy
BOV
AHEB5
SP TURISMO PNA
Delayed Upgrade Clock
ADVFN Logo
Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten

Werbung entfernen

Melden Sie sich für ein werbefreies Erlebnis an

Keine Werbung

Versuchen Sie es jetzt

Anzeigen behalten